BioSpace News Archive

NovellusDx announced it has completed an equity financing of $6 million.

Datavant announced that it has acquired Universal Patient Key (UPK).

A retrospective literature review published today in Pain Management examined the pharmacokinetic properties of intranasal (2mg or 4mg) and injectable (0.4 mg or 2 mg) formulations of naloxone approved by the U.S. Food and Drug Administration (FDA) to understand the speed of onset, adequacy and duration of the clinical effects.

AcelRx Pharmaceuticals, Inc. announced the publication of two studies commissioned by AcelRx analyzing errors involved with intravenous (IV) patient-controlled analgesia (PCA) systems in two peer-reviewed journals, Therapeutic Advances in Drug Safety and Expert Opinion on Drug Safety.

Acceleron Pharma Inc. announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.

The Medicines Company presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV.

LuxCath, LLC will showcase the next generation of its proprietary OmniView™ light-guided catheter ablation system at the 2018 Heart Rhythm Society (HRS) conference in Boston, May 9 to 12 at the Boston Convention Center.

LivaNova PLC announced it has successfully completed the divestiture of its Cardiac Rhythm Management (“CRM”) business to MicroPort Scientific Corporation (HK: 00853) (“MicroPort”) for $190 million in cash.

Paradigm Spine, LLC announced results of three subanalyses from studies of coflex® that further validate the efficacy and benefit to patients with lumbar spinal stenosis.

Jennifer will be responsible for regulatory strategy and execution across Celgene’s portfolio and will serve on the company’s Executive Committee.